The stability of Johnson & Johnson (NYSE: JNJ) has attracted investors for a long time. The healthcare company with more than 140,000 employees is a Dividend King that has raised its quarterly dividend annually for 60 consecutive years, including a 6.6% bump this year to $1.13 per share, resulting in a yield of about 2.58%. 

Over the past year, the stock price is up more than 10%, and so far in 2022, it is up more than 2.7%, well ahead of the drop of more than 17% so far this year by the S&P 500.

The company has built-in diversity because it is so large and operates in three segments: pharmaceuticals, medtech, and consumer healthcare. The last segment, the only one that is underperforming this year, will be spun off into a new stand-alone company next year called Kenvue.

Continue reading

Source Fool.com